Contraindications and people who should use Pemetinib with caution

Pemetinib (Pemetinib), as a selective fibroblast growth factor receptor (FGFR) inhibitor, can be clinically used to treat adult cholangiocarcinoma with FGFR2 rearrangement and myeloid/lymphoid tumors with FGFR1 rearrangement. However, like other drugs, pemetinib is not suitable for everyone. Understanding its contraindications and who should use it with caution is crucial to ensuring patient safety.

First of all, patients should be aware of the contraindications of pemetinib. The use of this drug must be strictly avoided in patients who are allergic to any component of pemetinib. Anaphylaxis may include, but is not limited to, rash, difficulty breathing, laryngeal edema and other serious symptoms, and may even be life-threatening. Therefore, before using pemetinib, doctors should inquire about the patient's allergic history in detail to ensure that the patient will not have an allergic reaction to any ingredients in the drug.

In addition to contraindications, there are some groups that require special caution when using pemetinib. Pemetinib may cause retinal pigment epithelial detachment (RPED), a side effect that may affect vision. This side effect may manifest as symptoms such as blurred vision, visual floaters, or light perception. Therefore, before initiating pemetinib therapy, patients should undergo a comprehensive ophthalmological examination, including optical coherence tomography, to evaluate the patient's ocular condition. Particularly for those patients who already have visual impairment, they need to be monitored more closely while taking pemetinib. The retinas of such patients may be more fragile and may respond more sensitively to medications. Doctors should weigh the risks and benefits of treatment based on the patient's specific situation and formulate a treatment plan that is most suitable for the patient.

In conclusion, although pemetinib is an effective therapeutic drug, its use guidelines must be strictly followed when using it, paying special attention to its contraindications and the groups for which it should be used with caution. Patients should be fully informed of this information to ensure the safety and effectiveness of treatment.